Germany contains costs but reimbursement reforms falter
This article was originally published in Clinica
Financial problems in Germany's healthcare system are due not to rapid spending growth but stem from the lack of a healthy revenue base in the public health insurance funds (Krankenkassen). Kevin Sullivan reviews the implications for the device industry.
You may also be interested in...
The European public assessment report for Kaftrio shows that EU regulators had concerns about whether Vertex’s triple drug combination for cystic fibrosis represented a new treatment paradigm.
Swissmedic says its good manufacturing practice certificates remain valid for longer than companies might assume. Separately, it is giving companies more time to conduct nitrosamine-related risk evaluations.
Stada has appointed a head of digital communications; PGEU elects new chair and vice-chair; and the new UK health claims committee unveils its first members.